An Open Label Extension Study in Subjects With Fragile X Syndrome
Public ClinicalTrials.gov record NCT01555333. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-Label Extension Study to Evaluate the Safety, Tolerability, and Pharmacokinetics in Subject With Fragile X Syndrome
Study identification
- NCT ID
- NCT01555333
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Seaside Therapeutics, Inc.
- Industry
- Enrollment
- 357 participants
Conditions and interventions
Conditions
Interventions
- arbaclofen Drug
Drug
Eligibility (public fields only)
- Age range
- 5 Years to 50 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 31, 2011
- Primary completion
- Jun 30, 2013
- Completion
- Jun 30, 2013
- Last update posted
- Jul 30, 2013
2011 – 2013
United States locations
- U.S. sites
- 23
- U.S. states
- 18
- U.S. cities
- 23
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Seaside Therapeutics Site #16 | Phoenix | Arizona | 85006 | — |
| Seaside Therapeutics Site #07 | Long Beach | California | 90806 | — |
| Seaside Therapeutics Site #10 | Sacramento | California | 95817 | — |
| Seaside Therapeutics Site #17 | Aurora | Colorado | 80045 | — |
| Seaside Therapeutics Site #01 | Miami | Florida | 33136 | — |
| Seaside Therapeutics Site #14 | Orange City | Florida | 32763 | — |
| Seaside Therapeutics Site #20 | Decatur | Georgia | 30033 | — |
| Seaside Therapeutics Site #02 | Chicago | Illinois | 60612 | — |
| Seaside Therapeutics Site #23 | Kansas City | Kansas | 66160 | — |
| Seaside Therapeutics Site #12 | Baltimore | Maryland | 21205 | — |
| Seaside Therapeutics Site #08 | Worcester | Massachusetts | 01605 | — |
| Seaside Therapeutics Site #03 | Columbia | Missouri | 65211 | — |
| Seaside Therapeutics Site #22 | New York | New York | 10029 | — |
| Seaside Therapeutics Site #04 | Staten Island | New York | 10314 | — |
| Seaside Therapeutics Site #24 | Chapel Hill | North Carolina | 27514 | — |
| Seaside Therapeutics Site #21 | Durham | North Carolina | 27710 | — |
| Seaside Therapeutics Site #05 | Akron | Ohio | 44308 | — |
| Seaside Therapeutics Site #15 | Oklahoma City | Oklahoma | 73117 | — |
| Seaside Therapeutics Site #11 | Media | Pennsylvania | 19063 | — |
| Seaside Therapeutics Site #19 | Nashville | Tennessee | 37212 | — |
| Seaside Therapeutics Site #25 | Houston | Texas | 77090 | — |
| Seaside Therapeutics Site #18 | San Antonio | Texas | 78258 | — |
| Seaside Therapeutics Site #13 | Seattle | Washington | 98121 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01555333, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 30, 2013 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01555333 live on ClinicalTrials.gov.